Anthropic launched a life-sciences–focused model and inked collaborations to let researchers query biological datasets in plain English, signaling Big Tech’s deeper push into drug discovery and translational research workflows. The Claude-for-Life-Sciences product targets tasks such as interrogating single-cell data and integrating multimodal datasets. Separately, Integrated DNA Technologies partnered with Profluent Bio to apply Profluent’s ProGen3 foundation model to enzyme design and scale-up, combining AI sequence design with IDT’s enzymology and manufacturing expertise. Together these moves underscore an industry pivot: AI models are moving from analytics aids to end-to-end partners in molecular design and assay development. For R&D teams, the rapid proliferation of life-science AI products raises questions about validation, reproducibility and regulatory readiness—but also promises to compress target-to-hit timelines and expand accessible expertise for smaller teams.